SEC Form 4 · accession 0001209191-18-010119
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Chodakewitz
Officer — EVP GMDA, CMO
Period of report
Feb 12, 2018
Accepted (ET)
Feb 14, 2018 · 6:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Feb 12, 2018 | S | 1,300 | $149.21 | D | 73,485 | D | |
| Common StockF3,F4 | Feb 12, 2018 | S | 1,100 | $150.47 | D | 72,385 | D | |
| Common StockF3,F5 | Feb 12, 2018 | S | 2,022 | $151.26 | D | 70,363 | D | |
| Common StockF3,F6 | Feb 12, 2018 | S | 400 | $152.62 | D | 69,963 | D | |
| Common StockF3,F7 | Feb 12, 2018 | S | 300 | $153.69 | D | 69,663 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $149.21 (range $148.80 to $149.64).
- F3Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $150.47 (range $149.83 to $150.76).
- F5Open market sales reported on this line occurred at a weighted average price of $151.26 (range $150.88 to $151.86).
- F6Open market sales reported on this line occurred at a weighted average price of $152.62 (range $152.09 to $152.96).
- F7Open market sales reported on this line occurred at a weighted average price of $153.69 (range $153.59 to $153.90).